Opinion|Videos|October 7, 2024
Exploring the Role of MOA and PDE4 Pathways in Pediatric Patients with Plaque Psoriasis
Author(s)Karan Lal, DO, MS, FAAD, Helen T Shin, MD
Key Takeaways
- PDE4 inhibitors modulate inflammatory responses by increasing intracellular cAMP levels, reducing pro-inflammatory cytokine production.
- These agents offer a targeted approach, potentially minimizing side effects compared to traditional therapies.
Panelists discuss how phosphodiesterase-4 (PDE4) inhibitors, with their ability to modulate inflammatory pathways, hold promise as therapeutic targets for immune-mediated diseases like pediatric plaque psoriasis, offering unique benefits by potentially reducing inflammation with a favorable safety profile for pediatric patients.
Advertisement
Video content above is prompted by the following:
- In light of the shifting treatment landscape, can you shed light on phosphodiesterase inhibitors-4 (PDE4), their nature, and why they hold promise as therapeutic targets for immune-mediated diseases like PP?
- How might its mechanism of action provide unique benefits for pediatric patients?
Advertisement
Related to this article
Elevate-Derm Summer 2026 faculty share practical lessons on hair loss exams, PIH, geriatric dermatology, and managing cholesterol rises on JAK inhibitors.
Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.
ATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events.
LRM will evaluate injectable rhPDGF-BB as a regenerative approach to infraorbital hollowing in a randomized phase 2b trial.
ORKA-001 achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B trial of moderate-to-severe psoriasis.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Revises TB Evaluation Guidance for SKYRIZI
2
Biologics, JAK Inhibitors, and Atopic March Data in Pediatric Atopic Dermatitis
3
ATI-052 Shows Rapid Improvements in Atopic Dermatitis
4
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
5